Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dynavax Technologies

G1 Therapeutics

ImmunoGen

Kadmon Hlds

Supernus Pharmaceuticals

Vertex Pharmaceuticals

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

7 Great Biotech Stocks to Buy and Hold Now

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?

MENLO PARK, Calif., May  14, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present novel immuno-oncology data from the selective cortisol receptor modulator relacorilant at the 2020 American Society of Clinical Oncology Annual Meeting. This year's annual meeting will be held in a virtual format from Friday, May 29 through Sunday, May 31, 2020. Following its presentation, a copy of our poster will be available at the Research & Pipeline / Publications tab of our website.

Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting

This biotech company has seen huge growth over the past five years.

Should You Climb on Board the Corcept Therapeutics Train?

Corcept Therapeutics sees its Relative Strength Rating move into the 80-plus level.
The post Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating appeared first on Investor's Business Daily.

Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating

Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.

Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2020 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates

Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice

1-800-FLOWERS.COM

iShares Core S&P U.S. Growth ETF

Kinross Gold

Vanguard Mega Cap Growth ETF

NeoPhotonics

Schwab U.S. Large-Cap Growth ETF

SPDR Portfolio S&P 500 Growth ETF

LendingTree

Vanguard Growth ETF

Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.

5 Growth ETFs & Stocks Set to Flourish in Spring

As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.

Corcept Therapeutics' Shares March Higher, Can It Continue?

Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock

MENLO PARK, Calif., April  01, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the publication of an abstract in the April-May supplemental issue of the Journal of the Endocrine Society (JES). The abstract describes the Phase 3 trial (entitled “GRADIENT”) of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia. Corcept’s poster describing the trial had been accepted for presentation at the 2020 Annual Meeting of the Endocrine Society (ENDO), which has been cancelled.

CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY

Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound?

MENLO PARK, Calif., March  12, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that former Gilead Sciences executive Gregg Alton has joined Corcept’s Board of Directors. Mr. Alton has also been appointed as Chair of the Corporate Governance and Nominating Committee of the Board of Directors.

Corcept Therapeutics Appoints Gregg Alton to Board of Directors

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

Corcept Therapeutics, Inc. (CORT) CEO Joseph Belanoff on Q4 2019 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Meets Q4 Earnings Estimates

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Corcept (CORT) Could Beat Earnings Estimates Again

During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.

What's in Store for Corcept (CORT) This Earnings Season?

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics (CORT) to Report Q4 Results: What Awaits?

MENLO PARK, Calif., Jan.  30, 2020  (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the stress hormone cortisol, today reported preliminary fourth quarter revenue of $87.9 million, compared to $66.8 million in the fourth quarter of 2018.  Preliminary 2019 revenue was $306.5 million, an increase of 22 percent from 2018. 

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

Despite The Clouds Hanging Over Korlym Sales, Corcept Therapeutics Still Looks An Attractive Investment

Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?

The company's fight to keep generic competition at bay took a turn for the worse.

News for Corcept Therapeutics Stock (CORT)